Kidney Cancer: The Next Decade

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 2018 Sep 16

PMID 30217855

Citations 110

Authors

Samra Turajlic

Charles Swanton

Chris Boshoff

Affiliations

Soon will be listed here.

Abstract

Chris Boshoff, Senior Vice President of Immuno-Oncology, Translational and Early Development at Pfizer, and colleagues Samra Turajlic and Charles Swanton from the Francis Crick Institute and University College London give us their personal point of view on new insights and future therapeutic approaches for renal cancer.

Citing Articles

Identification and validation of prognostic biomarkers in ccRCC: immune-stromal score and survival prediction.

Lyu F, Zhong Y, He Q, Xiao W, Zhang X BMC Cancer. 2025; 25(1):148.

PMID: 39871215 PMC: 11771106. DOI: 10.1186/s12885-025-13534-0.

High-throughput methylation sequencing reveals novel biomarkers for the early detection of renal cell carcinoma.

Guo W, Chen W, Zhang J, Li M, Huang H, Wang Q BMC Cancer. 2025; 25(1):96.

PMID: 39819319 PMC: 11737265. DOI: 10.1186/s12885-024-13380-6.

CLIP170 enhancing FOSL1 expression via attenuating ubiquitin-mediated degradation of β-catenin drives renal cell carcinoma progression.

Huang Y, Wen Z, Tao S, Yu Z, Wang X, Li X Cell Mol Life Sci. 2024; 81(1):467.

PMID: 39607512 PMC: 11604886. DOI: 10.1007/s00018-024-05504-9.

Role of DNA methylation transferase in urinary system diseases: From basic to clinical perspectives (Review).

Yang Y, Wang Y, Fan X, Xu X, Wang H, Wang X Int J Mol Med. 2024; 55(2).

PMID: 39575487 PMC: 11611324. DOI: 10.3892/ijmm.2024.5460.

Real-world effectiveness of first- and second-line anti-angiogenesis therapy in RCC: analysis of a UK-based population.

Waddell T, Pillai M, Armitage K, Graham D, Moran M, Dilleen M Future Oncol. 2024; 20(33):2547-2558.

PMID: 39382446 PMC: 11534105. DOI: 10.1080/14796694.2024.2385882.

References

Canadas I, Thummalapalli R, Kim J, Kitajima S, Jenkins R, Christensen C . Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat Med. 2018; 24(8):1143-1150. PMC: 6082722. DOI: 10.1038/s41591-018-0116-5. View

Chen W, Hill H, Christie A, Kim M, Holloman E, Pavia-Jimenez A . Targeting renal cell carcinoma with a HIF-2 antagonist. Nature. 2016; 539(7627):112-117. PMC: 5340502. DOI: 10.1038/nature19796. View

Turajlic S, Xu H, Litchfield K, Rowan A, Horswell S, Chambers T . Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. Cell. 2018; 173(3):595-610.e11. PMC: 5938372. DOI: 10.1016/j.cell.2018.03.043. View

Schram A, Voss M, Hyman D . Genome-Driven Paradigm for the Development of Selective Fibroblast Growth Factor Receptor Inhibitors. J Clin Oncol. 2016; 35(2):131-134. DOI: 10.1200/JCO.2016.70.5061. View

Turajlic S, Xu H, Litchfield K, Rowan A, Chambers T, Lopez J . Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. Cell. 2018; 173(3):581-594.e12. PMC: 5938365. DOI: 10.1016/j.cell.2018.03.057. View

Turajlic S, Litchfield K, Xu H, Rosenthal R, McGranahan N, Reading J . Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 2017; 18(8):1009-1021. DOI: 10.1016/S1470-2045(17)30516-8. View

Choueiri T, Motzer R . Systemic Therapy for Metastatic Renal-Cell Carcinoma. N Engl J Med. 2017; 376(4):354-366. DOI: 10.1056/NEJMra1601333. View

Mcdermott D, Huseni M, Atkins M, Motzer R, Rini B, Escudier B . Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018; 24(6):749-757. PMC: 6721896. DOI: 10.1038/s41591-018-0053-3. View

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

10.

Miao D, Margolis C, Gao W, Voss M, Li W, Martini D . Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018; 359(6377):801-806. PMC: 6035749. DOI: 10.1126/science.aan5951. View

11.

Mitchell T, Turajlic S, Rowan A, Nicol D, Farmery J, OBrien T . Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal. Cell. 2018; 173(3):611-623.e17. PMC: 5927631. DOI: 10.1016/j.cell.2018.02.020. View

12.

Yao X, Tan J, JunLiang Lim K, Koh J, Ooi W, Li Z . Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma. Cancer Discov. 2017; 7(11):1284-1305. DOI: 10.1158/2159-8290.CD-17-0375. View